Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 1997

View Archived Issues

Astra year-end report January-December 1996

IDEC Pharmaceuticals reports 1996 fourth-quarter and year-end results

Magainin announces 1996 financial results

NABI reports 1996 financial results

WF-10 undergoes further clinical studies for AIDS

CoCensys initiates migraine trial

Matrix selects distribution partner for Italy

ChemTrak H. pylori test approved

Pfizer develops ACAT inhibitors

Akzo Nobel discloses MAb for HCV detection

Antidiabetic/hypolipidemic agents from Sumitomo Metal

Steroidal antitumor agents described by Taisho

Knoll reveals compounds with 5-HT1A receptor affinity

HLE inhibitors from P&U

ET antagonists from Warner-Lambert

Protein kinase inhibitors reported by Roche

Lp-PLA2 inhibitors disclosed by SKB

Selective stromelysin-1 inhibitor described by Merck & Co.

Orally active inhibitor of Ras farnesylation reported by Schering-Plough

GelTex receives U.S. patent for CholestaGel

GenPharm and Centocor to codevelop human antibodies

Novo Nordisk to develop compounds discovered by Indian research foundation

Clinical results for Murex/Innogenetics HIV-1 RT test

IDEC and Roche submit applications for IDEC-C2B8

Biogen signs distribution agreement with Genesis Pharma

Protein Design Labs grants license to Biogen for humanized antibodies

Medarex acquires Houston Biotechnology

SangStat receives European patent for Xenoject drugs

Caelyx available in additional countries

RAS inhibitors reduce mortality in a model of cerebral ischemia

Update on Sparta's asulacrine

Oral mucositis treatment proceeds to phase II

Novel post-Amadori inhibitors identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...